Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 17;11:6410. doi: 10.1038/s41467-020-19917-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a CD8+ T cell content of TCGA UPS by sarcoma immune class (SIC) and murine sarcomas by CIBERSORTx. P values shown for each group vs transplant tumors by two-sided Wilcoxon test. Sample sizes as follows: SIC A (n = 6), SIC B (n = 21), SIC C (n = 7), SIC D (n = 9), SIC E (n = 17), primary (n = 8), and transplant (n = 4). b Frequency of activated (Lag3+ Tim3+) CD8+ T cells by CyTOF. Data show mean ± SEM by two-way ANOVA. c Mice with transplant sarcomas received either αPD-1 or isotype control antibodies, αCD8 or isotype control, and 0 Gy (solid) or 20 Gy (dashed) when tumors reached >70 mm³. Surviving mice were censored 164 days after treatment (*P = 0.002). Sample sizes: Iso/Iso + 0 Gy n = 6, Iso/αCD8 + 0 Gy n = 9, αPD-1/Iso + 0 Gy n = 8, αPD-1/αCD8 + 0 Gy n = 9, Iso/Iso + 20 Gy n = 9, Iso/αCD8 + 20 Gy n = 7, αPD-1/Iso + 20 Gy n = 7, αPD-1/αCD8 + 20 Gy n = 10. d Mice with transplant sarcomas received either αPD-1 or isotype control antibodies, αCD4 or isotype control, and 0 Gy (solid) or 20 Gy (dashed) when tumors reached >70 mm³. Surviving mice were censored 100 days after treatment (*P = 0.002). Sample sizes: Iso/Iso + 0 Gy n = 13, Iso/αCD4 + 0 Gy n = 15, αPD-1/Iso + 0 Gy n = 15, αPD-1/αCD4 + 0 Gy n = 14, Iso/Iso + 20 Gy n = 13, Iso/αCD4 + 20 Gy n = 16, αPD-1/Iso + 20 Gy n = 14, αPD-1/αCD4 + 20 Gy n = 17. e tSNE plot of lymphoid cell scRNA-seq subclustering from all tumor and treatment groups. f Distribution of lymphoid cells, separated by tumor and treatment type. n = 4 tumors per group for transplant, n = 5 tumors per group for primary. g Expression levels of marker genes. h Pathways with significantly different activities per cell using GSVA between CD8+ T cells from untreated (isotype control) primary tumors versus transplant tumors (n = 2473 cells analyzed). Pathways shown are significant at false-discovery rate <0.01. For c and d, survival curves estimated using Kaplan–Meier method; pairwise significance determined by log-rank test and Bonferroni correction. Source data are provided as a Source data file.